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Impact of an Innovative Educational Strategy on Medication
Appropriate Use and Length of Stay in Elderly Patients
Graziamaria Corbi, MD, PhD, Giovanni Gambassi, MD, Gennaro Pagano, MD,
Giusy Russomanno, PharmD, Valeria Conti, PhD, Giuseppe Rengo, MD, PhD,
Dario Leosco, MD, PhD, Roberto Bernabei, MD, Amelia Filippelli, MD, and Nicola Ferrara, MD
Abstract: To evaluate the impact of an educational strategy on
potentially inappropriate medications (PIMs) and length of stay in
hospitalized elderly patients.
Design:An open study, with two cross-sectional surveys interspersed
with an educational program (PRE phase and POST phase), has been
performed in order to compare the PIMs number before and after the
introduction of an educational strategy. The study included 2 phases:
PRE, in which patients were enrolled as control group; POST, in
which an educational strategy on the PIMs use was introduced
among physicians, and patients were enrolled as intervention group.
Setting: Italian residential rehabilitation Centre.
Inclusion criteria were 2 active chronic diseases and the current
use of 4 medications.
The educational strategy consisted of a 3-day course on strategies
to prevent PIMs and a computerized tool running on a Personal Digital
Assistant (PDA) device to check for PIMs.
Outcomes: The primary was the PIMs number, the secondary the
length of stay.
Results: A total of 790 patients, 450 controls and 340 cases, were
enrolled. According to the Beers criteria, 52.3% of the study
population received 1 PIMs, 18.73% 2, and 2.4% 4 PIMs. A
significant reduction of PIMs (P¼ 0.020) and length of stay
(P< 0.0001) were seen in the intervention group. At multivariate
analysis, PIMs significantly correlated with age, drugs number, and
the intervention, and the length of stay significantly correlated with
disease count, comorbidities, and intervention.
These data suggest that our educative instrument may be useful in
reducing the PIMs number and length of hospitalization in elderly
with a high number of drugs and comorbidities.
(Medicine 94(24):e918)
Abbreviations: ADR = adverse drug reactions, AIC = Marketing
Authorisation code, ATC = Anatomical Therapeutic Chemical (ATC)
code, CIRS = Cumulative Illness Rating Scale, doi = digital object
identifier, ICD 9-CM = International Classification of Diseases, 9th
revision, Clinical Modification, interRAI = International Residential
Assessment Instrument, IQR = interquartile range, PDA = Personal
Digital Assistant, PIMs = potentially inappropriate medications,
SPSS = Statistical Package for Social Science, VMD =
multidimensional geriatric assessment.
INTRODUCTION
A ppropriateness indicates that the potential benefits of amedication outweigh the potential risks and represents a
crucial point for the choice of the best drug. Inappropriate
medications can be defined as ‘‘medications or medication
classes that should generally be avoided in persons 65 years
or older because they are either ineffective or they pose
unnecessarily high risk for older persons and a safer alternative
is available.’’1 Many elderly patients routinely receive poten-
tially inappropriate medications (PIMs), such as sedative-hyp-
notics, analgesics, histamine blockers, antibiotics, laxatives that
can cause harm, directly or through interactions.2–6
The prevalence of inappropriateness increases with the age
reaching a 70% in a geriatric hospital setting.7 PIMs are common
in older patients for the physiological changes related to the age
and for a greater degree of frailty and multiple coexisting con-
ditions. In turn, exposure to inappropriate therapy is associated
with an increase in terms of adverse events,8 morbidity, mortality,
and health costs.9,10 Several different tools1,11 have measured
inappropriateness and specific criteria have been formulated to
identify PIMs.1,11–13 However, the applicability and effects in
clinical practice for these variousmeasures remains uncertain.14,15
Several studies have been conducted on this topic with
inconclusive results. Computer data entry and feedback pro-
cedures, which have been shown to decrease polypharmacy
and drug–drug interactions,16 visual identification of medicines,
continuous medication review and thorough patient education to
optimize polypharmacy,17 computerized decision support,18 mul-
tidisciplinary case conferences19 represent only somekind of tools
used to reduce PIMs. However, conclusive evidence is currently
lacking, probably because there were heterogeneities in settings,
study population and evaluationmethods, and the optimalmethod
to avoid inappropriate medication is at present unknown. The aim
of this study was to evaluate the impact of an educational strategy
on PIMs incidence in elderly patients 65 years and older admitted
postacutely to a residential rehabilitation medical centre in Italy.
MATERIALS AND METHODS
Patients’ information and consent forms were approved
by the Ethical committee of the coordinating Centre at the
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University of Molise. The study was conducted in accordance
with the World Medical Association’s 2008 Declaration of
Helsinki. This report adheres to the consolidated standards
for the reporting of observational trials and was written accord-
ing to the STROBE guidelines for Observational Studies in
Epidemiology.20
Study Design
We conducted an open study, with 2 cross-sectional sur-
veys interspersed with an educational program (PRE phase and
POST phase),21 in order to compare patients PRE (control
group) and POST (intervention group) the introduction of an
educational/informative strategy in term of number of PIMs and
of length of stay. The study included 2 different phases. In an
initial phase (PRE) lasting 4 months all patients consecutively
admitted to the rehabilitation units participating to the study
were enrolled and followed up until discharge. After this initial
phase, an educational/informative strategy on the use of inap-
propriate medications was introduced and during a second 4
months period (POST) all consecutive patients admitted to the
participating units were recruited in a similar fashion as phase
one. The number of PIMs was evaluated at the discharge, using
a specific software (Farmadati library, http://www.farmadati.it).
Population
Patients 65 years and older were enrolled in the study at
admission to the rehabilitation unit. Inclusion criteria were the
presence of 2 or more active chronic medical conditions (car-
diovascular-respiratory system, gastrointestinal system, geni-
tourinary system, muscle-skeletal system, neuropsychiatric
system, and general system) and the current use of 4 or more
concomitant medications. The postacute intensive rehabilitation
Centre admitted patients discharged from hospitals for acute
cardiovascular and neurological accidents. All patients were
treated with the therapy received at the moment of the
hospital’s discharge.
Intervention
The education strategy consisted of a 3-day intensive
training course and of a computerized tool for physicians.
The education course, provided by specialists on inappropriate
prescriptions, was a training module on epidemiology, patho-
genesis and strategies to prevent drug inappropriateness, inter-
actions and Adverse Drug Reactions (ADRs) including the
principles of geriatric pharmacology, the disease itself, and
factors that can lead to complications.
The specifically qualifying elements of the training were
appropriately selected based also on an evaluation of the
common problematic areas of elderly patients and based also
on information gathered in the patient group recruited in the
control period. Educational leaflets were prepared in the form of
a self-study program that includes information on the previously
mentioned topics and after every educational session they were
given to the physicians. The authors developed all the edu-
cational materials. The training sessions also included teaching
the use of the computerized tool.
The computerized tool worked on a Personal Digital
Assistant (PDA) device to check for inappropriateness prior
to any new medication prescription. The tool consisted of an
information system already embedded in the commercially
available Atl@nte system, which consults the Pharmaceutical
Handbook for criteria of inappropriateness. The application
started by using a special icon installed on the PDA. The
system, after authentication with a password, presented a grid
with the list of drugs researched and selected, and clickable
buttons (drug research, inappropriateness of each drug with
detailed information about the drug, deletion of the drug
selected, cleaning the grill). The grid for each selected drug
contained the following information: Marketing Authorisation
code (AIC), Anatomical Therapeutic Chemical (ATC) code,
short description of the drug and the active ingredient.
After entering the search criteria by clicking on the ‘‘Find’’
button at the bottom of the screen was shown the list of drugs
that met the criteria. Once decided which drug to select by
clicking on the button ‘‘Select the drug,’’ the search form closed
and again appeared the first screen containing the list of selected
drugs. Concerning the inappropriateness, the system showed
whether in the drugs list of the grid, there were PIM, and these
were highlighted with three different colors: RED (to avoid
always), ORANGE (rarely appropriate), YELLOW (some
indications). By clicking the ‘‘inappropriateness,’’ the program
reported the additional notes related to the selected drug. The
PIMs were visualized by the PDA at the moment of the drug
prescription in the intervention group, but the physicians could
or could not decide to confirm the drug administration. In the
intervention group any therapy in all patients was confirmed or
modified at admission by using the PDA. The PIMs number was
determined at the end of the study for both groups.
Endpoints
The primary outcomes of the study were the cumulative
number of PIMs. Secondary endpoint was the length of stay. For
the definition of inappropriateness, we used Beers 200312
criteria. The number of PIMs were monitored through dedicated
software implemented using the Farmadati library (http://
www.farmadati.it) and evaluated at patient discharge. The
system was supported at the Handbook of Pharmaceutical
Company Farmadati Italy srl and the system Atl@nte for the
period of the project used the drug-index of the company. With
regard to the aspects of optimization of therapy, the appropri-
ateness and the best compliance of therapy were referred to
all drugs.
Data Collection
For data collection, we used the centralized Atl@nte
system that contains an electronic medical record that allows
data entry online. The Atl@ante system is an organizational and
management tool, which includes multiple geriatric assessment
instruments including the Italian version of the International
Residential Assessment Instrument (interRAI). It targets people
over 65 years who require needs assessment for access to
publicly funded services, and consists of a multidimensional
geriatric assessment (VMD) system intended to determine a
hospitalized older persons’ medical, psychosocial, and func-
tional capacity and needs. Its objective is to develop an overall
plan for treatment and long-term follow-up based on a common
set of standardized items that can be used in various care
settings. The electronic medical record contains: (a) physical
examination and clinical assessment, (b) the Cumulative Illness
Rating Scale (CIRS) with reference to conditions classified
according to the International Classification of Diseases, 9th
revision, Clinical Modification (ICD 9-CM), (c) VMD includ-
ing the Geriatric Depression Scale and the EURO QoL 5D, (d)
medical history including previous tests and examinations, (e)
medications prescribed and administered, (f) clinical daily notes
with indications of all diagnostic tests, (g) a record about
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healthcare-related resource use. Training sessions for using the
electronic health record were conducted at the onset of data
collection and continuous support and a manual explaining the
use of the software were provided.
Statistical Analysis
Continuous variables are expressed as mean standard
deviation and compared by the use of Student t test (normally
distributed) or as median interquartile range value and com-
pared by the use of Mann–Whitney U test (not normally
distributed), as appropriate. Normality of data distribution
was evaluated using the Kolmogorov-Smirnov test. Not nor-
mally distributed continuous variables were natural log trans-
formed. Categorical variables are expressed as proportion and
compared by use of x2 test.
Correlation between variables was assessed by linear
regression analysis and variables that revealed a statistical
significance at univariate model where then included in a
multivariate analysis.
To determine the independent predictors of the number of
PIMs, linear regression analysis was performed and variables
achieving P< 0.10 on univariate analysis were then included in
a multivariate analysis. To fulfill the assumption of linearity of
the not normally distributed variables, they were included in the
linear regression analysis as their natural logarithmic function.
The same analysis was performed for the length of stay, as
dependent variable. All data were collected in an Excel database
and analyzed by Statistical Package for Social Science (SPSS)
version 19.0 (SPSS, Inc, Chicago, IL). Statistical significance
was accepted at P< 0.05.
Sample Size
The sample size was estimated by referring to epidemiolo-
gical studies and intervention carried out on elderly patients. We
expected that the intervention would lead to a reduction of PIMs
of at least 10%. Our study was powerful enough to be able to
detect with a power of 80% (beta¼ 20%) to 2-tailed significance
level of 5% (alpha 5%), a reduction of PIMs from 65.1% to
55.0%. The relative group size was 57% (n¼ 450) for the group
with highest expected incidence (without intervention) and 43%
(n¼ 340) for the lowest expected incidence (with intervention).
RESULTS
Study Patients
A total of 790 patients, 450 during the PRE phase acting as
controls and 340 cases during the POST phase after the imple-
mentation of the educational/informative strategy were
TABLE 1. Demographic Characteristics of the Study Population
Total Population
(N¼ 790)
Control
(N¼ 450)
Intervention
(N¼ 340) P-Value
Age, means (SD), years 75.1 (5.6) 75.5 (5.6) 74.7 (5.5) 0.057
Sex, %, M/F 58.8/41.2 57.8/42.2 60.3/39.7 0.477
Disease count, means (SD) 5.56 (3.51) 5.57 (3.78) 5.55 (3.12) 0.917
F¼ female, M¼male, SD¼ standard deviation.
TABLE 2. Other Characteristics of the Study Population
Total Population
(N¼ 790)
Control
(N¼ 450)
Intervention
(N¼ 340) P-Value
Drugs number, means (SD) 6827 8.26 (2.9) 9.15 (3.1) <0.0001
Length of stay 36.87 (24.40) 43.26 (26.56) 28.20 (17.85) <0.0001
CAD, N (%) 495 (62.7) 284 (63.11) 211 (62.06) 0.834
Psychiatric disorder (anxiety), N (%) 392 (49.6) 224 (49.78) 168 (49.41) 0.976
Diabetes, N (%) 359 (45.4) 210 (46.67) 149 (43.82) 0.466
COPD, N (%) 229 (29.0) 134 (29.78) 95 (27.94) 0.605
Neurological diseases, N (%) 206 (26.08) 106 (23.56) 100 (29.41) 0.063
Heart failure, N (%) 171 (21.6) 101 (22.44) 70 (20.59) 0.555
Urinary infections (last 30 days), N (%) 96 (12.2) 44 (9.78) 52 (15.29) 0.017
Cancer, N (%) 87 (11.0) 50 (11.11) 37 (10.88) 0.939
Fractures, N (%) 50 (6.3) 30 (6.67) 20 (5.88) 0.667
Pulmonitis, N (%) 30 (3.8) 20 (4.44) 10 (2.94) 0.280
Cardiovascular drugs, N (%) 628 (79.5) 367 (81.55) 261 (76.76) 0.099
Anticoagulant drugs, N (%) 598 (75.7) 339 (75.33) 259 (76.18) 0.784
Hypolipidemic drugs, N (%) 374 (47.3) 205 (45.55) 169 (49.71) 0.247
Antidiabetic drugs, N (%) 296 (37.5) 168 (37.33) 125 (36.76) 0.928
Antinflammatory drugs, N (%) 190 (24.1) 96 (21.33) 94 (27.65) 0.040
Neurological drugs, N (%) 50 (6.3) 15 (3.33) 35 (10.29) <0.0001
CAD¼ coronary artery diseases, COPD¼ chronic obstructive pulmonary disease, SD¼ standard deviation.
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enrolled, representing the intervention group. The main socio-
demographic characteristics and drugs number of the 790
subjects are shown in Table 1.
Median number of different drugs prescribed to each indi-
vidual was 8 (interquartile range [IQR] 7, 10, range 1–22) in the
control and 9 (IQR 7, 11, range 1–22) in the intervention group.
Although the disease count was similar in the 2 groups, the
intervention one was characterized by a significant higher CIRS
comorbidity and severity indexes in both 13 and 14 parameters
comparing to the controls and some significant differences were
also found in the frequency of urinary infections (P¼ 0.017)
between the 2 groups (Table 2 and Figure 1A). Nevertheless, a
significant difference was reported in the length of stay with an
average duration lower in the intervention group compared to the
control (P< 0.0001; Table 2). In both groups, the cardiovascular
molecules represented the main drugs used, with significant
difference only in the higher use of antinflammatory and neuro-
logical drugs in the intervention in respect to the control group
(Table 2).
Inappropriate Prescriptions
By using Beers 2003 criteria,11 413 persons 65 years
(52.3% of the study population) received 1 or more PIMs, 148
(18.73% of the study population) received 2 or more, and 19
people (2.4%) were affected by 4 or more PIMs with a maximum
of 7 different indicator hits affecting 1 person (Table 3). The total
number of hits was 626. The most frequent drugs responsible of
PIMs were represented by antiarrhythmics in both groups. The
only differencewas in the intervention group a lower incidence of
antinflammatory/antirheumatic PIMs (P¼ 0.005; Figure 1B).
A significant reduction of PIMs was seen in the interven-
tion group (0.86 (1.05) vs 0.70 (0.89); P¼ 0.020; 95%
CI¼ 0.026–0.305) especially for the category with more than
4 inappropriate prescriptions. The lower number of inappropri-
ate prescriptions was better evident by the lower proportion of
patients receiving 1 or more potentially inappropriate medi-
cation in relation to the total number of pharmaceutical sub-
stances used in the intervention versus the control group
(Figure 2; P< 0.0001). At multivariate analysis, the predictors
of PIMs were age, number of drugs, and the intervention
FIGURE 1. (A) Diseases percentage distribution of study popu-
lation stratified by control and intervention group. Some differ-
ences were found between control and intervention group. In the
intervention there were more urinary infections in the last 30 days
than in the control group;

P¼0.017. (B) Distribution of the
inappropriate drugs for drug category in the study. The most
frequent drugs responsible of potentially inappropriate medi-
cations (PIMs) were represented by the antiarrhythmics in both
groups. The only significant difference was found in the% of PIMs
for antinflammatory/antirheumatic drugs;

P¼0.005.
TABLE 3. Prevalence of Potentially Inappropriate Medications
(PIMs) per Person According to the Beers and Zhan Criteria
Indicator
hits per
person (n)
Control Intervention
People
Affected
(n)
% of
Total
Sample
People
Affected
(n)
% of
Total
Sample
1 156 34.7 109 32.1
2 69 15.3 42 12.4
3 11 2.4 7 2.1
4 13 2.9 6 1.8
Total 249 55.3 164 48.4
P¼ 0.035. FIGURE 2. Proportion of patients receiving 1 potentially inap-
propriatemedication (PIMs), in relation to the drugs total number.
Corbi et al Medicine  Volume 94, Number 24, June 2015
4 | www.md-journal.com Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
(Table 4). At multivariate analysis, length of stay significantly
correlated with disease count, comorbidity index, and the
intervention (Table 5).
DISCUSSION
In our study, the used educative instrument was able to
significantly reduce the number of PIMs (Figure 2), and the
length of hospitalization, suggesting as this tool could be very
helpful especially in complicated patients with several comor-
bidities and drugs.
Several studies showed that PIMs are common in ambu-
latory settings, in nursing homes and in Emergency depart-
ments, and that inappropriate therapy is associated to increased
Adverse Drugs Reactions, morbidity, mortality, and resource
use.9 The optimization of drug prescription is thus becoming an
objective necessity of health systems.22 Many studies based on
the use of educative interventions demonstrated their efficacy in
reducing the inappropriate prescriptions. Avorn et al23
examined the impact of an academic detailing intervention
consisting in a clinical education of the medical staff in the
principles of geriatric psychopharmacology on the use of
psychotropic medications in nursing home residents. Similar
to our study, inappropriateness scores for use of psychoactive
drugs declined significantly in the intervention nursing homes
compared with those from the control. Mattison et al24 also
conducted a study to determine whether a computerized pro-
vider system could decrease orders for potentially inappropriate
medications as defined by a subset of Beers list medications in
hospitalized older patients. The authors concluded that specific
alerts embedded into a computer-decision system, used in
patients over 65 years, can decrease the number of inappropriate
prescriptions quickly and specifically. However, the general-
izability of most of these studies is limited because the inves-
tigators developed their own software programs to conduct the
intervention that are not available to the public.25 Recently it has
been demonstrated that computer-based systems can be imple-
mented as decision resources, similar to the system found to be
effective by Mattison et al24 for instance as a pop-up window in
electronic medical records systems.26
In our study, the use of the tool was able to significantly
reduce the length of hospital stay (Table 4), a well-known risk
factor for mortality and complications.26–28 In particular, hos-
pital length of stay is a potentially useful measurement of
TABLE 4. Linear Regression Analysis for Potentially Inappropriate Medications (PIMs)
Variables Univariate Analysis Multivariate Analysis
b 95% CI P-Value b 95% CI P-Value
Lower Upper Lower Upper
Age 0.067 0.001 0.024 0.061 0.067 0.000 0.024 0.046
Sex 0.026 0.194 0.088 0.461 — — — —
Disease count 0.053 0.035 0.005 0.140 — — — —
No. of drugs 0.293 0.074 0.117 <0.0001 0.313 0.080 0.124 <0.0001
Length of stay 0.004 0.003 0.003 0.913 — — — —
Intervention 0.083 0.305 0.026 0.020 0.123 0.381 0.113 <0.0001
CIRS severity 0.035 0.121 0.354 0.335 — — — —
CIRS comorbidity 0.033 0.021 0.057 0.363 — — — —
CI¼ confidence interval,; CIRS¼Cumulative Illness Rating Scale. P-value is referred to univariate and multivariate analysis against PIMs.
TABLE 5. Linear Regression Analysis for Length of Stay
Variables Univariate Analysis Multivariate Analysis
b 95% CI P-Value b 95% CI P-Value
Lower Upper Lower Upper
Age 0.098 0.122 0.734 0.006 0.041 0.111 0.466 0.229
Sex 0.024 2.273 4.664 0.499 — — — —
Disease count 0.173 0.737 1710 <0.0001 0.111 0.328 1.491 0.002
No. of drugs 0.060 1.050 0.076 0.090 0.002 0.566 0.596 0.959
PIMs 0.004 1.627 1.818 0.913 — — — —
Intervention 0.310 18.532 11.978 <0.0001 0.312 18.244 11.759 <0.0001
CIRS severity 0.054 1.334 10.104 0.133 — — — —
CIRS comorbidity 0.085 0.191 2.049 0.018 0.081 0.079 2.060 0.034
CI¼ confidence interval, CIRS¼Cumulative Illness Rating Scale, PIMs¼ potentially inappropriate medications. P-value is referred to univariate
and multivariate analysis against length of stay.
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morbidity and a major determinant of the cost of medical care.28
Therefore, therapy should be guided by the appropriateness that
is accomplished through the evaluation of the risk/benefit ratio,
essentially when the potential benefits of a drug outweigh the
potential risks. Starting from the consideration that the pro-
blems related to drug intake include factors related to the patient
(emotional factors, simple forgetfulness, lack of training/infor-
mation) and the doctor (deficit of information to the patient,
complex therapies, bad doctor/patient relationship), it is necess-
ary to develop strategies involving patients, families, care-
givers, and family physicians engaged in an essential role in
the correct medication, in the reduction of iatrogenic damage
and increasing the adhesion.29–31,32
Limitations
A limitation of our study could be considered the absence
of ADRs as primary endpoint. The reason of this lack is that
ADRs are objective of a greater study that our group is
performing. An additional limitation could be represented by
the use of Beers 2003 instead of 2012 criteria. This lack was
related to the starting date of the project that was settled before
the Beers 2012 criteria publication. However, in looking at the
updated ‘‘drugs-to-avoid’’ list, it is important to note that of
those therapeutic classes/medications removed from the
previous criteria, 7 were due to drugs being withdrawn from
the market since the last time the criteria were published in 2003
(eg, propoxyphene) and 1 removal was due to the lack of
evidence that long-term stimulant laxatives lose effectiveness
or result in unacceptable adverse effects.32 Then, the recom-
mendation NOT to use >325mg per day of ferrous sulfate to
treat iron deficiency anemia (that represented 1 of the major
causes of PIM in our study) applies to adults of all ages and thus
was dropped.33,34
CONCLUSIONS
Controlled studies articulated through the use of ‘‘tools’’
computing should be planned in order to give a correct answer
to the increasing need of prescription appropriateness in poly-
pathology elderly patients who take several different drug
treatments. On this basis, these data suggest that our educat-
ive/informative instrument may be useful in reducing the
number of inappropriate prescriptions and length of hospital-
ization, especially in more severely ill patients and with a high
number of used drugs, representing, therefore, an important
approach in the management of elderly patients characterized
by polypharmacotherapy and comorbidity.
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